Evidence map›Paper›PMID 33059834›Full record

ReviewJournal of the American College of Cardiology2020

Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review.

Maria Giovanna Trivieri, Paolo Spagnolo, David Birnie, Peter Liu, Wonder Drake, Jason C Kovacic, Robert Baughman, Zahi A Fayad, Marc A Judson

Open access · greenAbstract readReview
In one paragraph

Review in Journal of the American College of Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 1 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 1 synthesis or guideline pooled it, 198 citations in OpenAlex.

  1. The prognostic role of cardiac positron emission tomography imaging in patients with sarcoidosis: A systematic review.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Redefining Cardiac Sarcoidosis with Advanced Imaging and Therapeutic Strategies.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
  11. Article
  12. Cardiovascular Manifestations and Immunobiology of Sarcoidosis.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Cardiac sarcoidosis recurrence post-heart transplant: A critical literature and case report.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  19. Outcomes of catheter ablation in cardiac sarcoidosis patients with ventricular tachycardia: a propensity score-matched retrospective analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025
    Article
  20. Review

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 3 countries.

Maria Giovanna TrivieriThe BioMedical Engineering and Imaging Institute (BMEII), Icahn School of Medicine at Mount Sinai, New York, New York; Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: mariagiovanna.trivieri@mountsinai.org.
Paolo SpagnoloSection of Respiratory Diseases, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy.
David BirnieDivision of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Peter LiuDivision of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Wonder DrakeDivision of Infectious Disease, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Jason C KovacicCardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Robert BaughmanDepartment of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio.
Zahi A FayadThe BioMedical Engineering and Imaging Institute (BMEII), Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: https://twitter.com/zahifayad.
Marc A JudsonDivision of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York.
University of Ottawa · CAAlbany Medical Center Hospital · USCardiovascular Institute of the South · USIcahn School of Medicine at Mount Sinai · USTwitter (United States) · USUniversity of Cincinnati · USUniversity of Padua · ITVanderbilt University · US

Funding

MR/PET Imaging of coronary atherosclerosisR01HL071021 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FAYAD, ZAHI A. · 2002 to 2019
$7.8M
Atherosclerosis in cocaine addiction: imaging risk with PET/MRR01DA049547 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nelly Alia-Klein, Zahi A. Fayad · 2022 to 2026
$3.9M
Microbial induction of sarcoidosis CD4+ T cell dysfunctionR01HL117074 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL, DRAKE, WONDER P. · 2013 to 2017
$3.8M
MSHS Translational Science HubKL2TR001435 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MOSKOWITZ, ALAN J · 2015 to 2019
$3.8M
Understanding the Molecular Mechanisms of Fibromuscular DysplasiaR01HL148167 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KADIAN-DODOV, DANIELLA, KOVACIC, JASON CIRIL · 2020 to 2023
$2.8M
Toward Therapeutic Manipulation of Endothelial to Mesenchymal TransitionR01HL130423 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ISHIKAWA, KIYOTAKE, KOVACIC, JASON CIRIL · 2016 to 2020
$2.1M
NCATS NIH HHS KL2 TR001435NHLBI NIH HHS R01 HL071021NHLBI NIH HHS R01 HL117074NHLBI NIH HHS R01 HL148167NIDA NIH HHS R01 DA049547
6 · The paper itself

Abstract

Sarcoidosis is a complex disease with heterogeneous clinical presentations that can affect virtually any organ. Although the lung is typically the most common organ involved, combined pulmonary and cardiac sarcoidosis (CS) account for most of the morbidity and mortality associated with this disease. Pulmonary sarcoidosis can be asymptomatic or result in impairment in quality of life and end-stage, severe, and/or life-threatening disease. The latter outcome is seen almost exclusively in those with fibrotic pulmonary sarcoidosis, which accounts for 10% to 20% of pulmonary sarcoidosis patients. CS is problematic to diagnose and may cause significant morbidity and death from heart failure or ventricular arrhythmias. The diagnosis of CS usually requires surrogate cardiac imaging biomarkers, as endomyocardial biopsy has relatively low yield, even with directed electrophysiological mapping. Treatment of CS is often multifactorial, involving a combination of antigranulomatous therapy and pharmacotherapy for cardiac arrhythmias and/or heart failure in addition to device placement and cardiac transplantation.

Indexed as

Antibodies, MonoclonalCardiomyopathiesHumansMagnetic Resonance Imaging, CineReview Literature as TopicSarcoidosisSarcoidosis, PulmonaryAntibodies, Monoclonalbiomarkerscardiac sarcoidosisimagingpulmonary sarcoidosis

Identifiers

PMID33059834
PMCPMC7808240
OpenAlexW3093290872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.